Halofuginone (RU-19110) hydrobromid, a febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity.

Halofuginone (RU-19110) hydrobromid, a febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity.

(E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is a broad spectrum Phospholipase A2 (PLA2) inhibitor and TRP channel blocker. (E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is also an effective reversible inhibitor of calcium-activated chloride channels, has potential to treat arrhythmia.

(±)-Zanubrutinib ((±)-BGB-3111) is the racemate of Zanubrutinib (HY-101474A). (±)-Zanubrutinib inhibits Bruton’s tyrosine kinase (Btk) with an IC50 of 0.63 nM.

ITX5061 is a type II inhibitor of p38 MAPK and also an antagonist of scavenger receptor B1 (SR-B1).

2′,7′-Dichlorofluorescein diacetate (DCFH2-DA) is a cell-permeable fluorescent probe. 2′,7′-Dichlorofluorescein diacetate can be used to detect the generation of reactive oxygen intermediates and for assessing the overall oxidative stress in toxicological phenomenon.

Kamebakaurin is a diterpene isolated from Isodon japonicus, it is a potent inhibitor of NF-kappaB activation by directly targeting DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-κB target genes. It can be used in research of pathological conditions such as inflammation and cancer.

Kamebakaurin is a diterpene isolated from Isodon japonicus, it is a potent inhibitor of NF-kappaB activation by directly targeting DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-κB target genes. It can be used in research of pathological conditions such as inflammation and cancer.

BI605906 is a selective inhibitor of IKKβ with an IC50 of 380 nM when assayed at 0.1 mM ATP, suppressing the phosphorylation and activation of IKKβ, modulating NF-κB signalling. It also inhibits the insulin-like growth factor 1 (IGF1) receptor, with an IC50 of 7.6 μM. BI605906 effectively blocks TNF-α-dependent IκB degradation and reduces the expression […]

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer. IC50 value:Target: c-MetMore details please refer to Patent WO 2012015677 A1.